iBio, Inc. — Form 10-K
Filed August 28, 2026 · analyzed by the Periodic Agent
10-K
▲ Likely positive
significance 72/100
What the filing says
iBio, Inc. (market cap ~$22.4M) entered into an Assignment and Exclusive License Agreement with AstralBio, Inc. effective August 27, 2026. iBio acquired full ownership of AstralBio's Amylin Target intellectual property (antibodies, patents, know-how) and an exclusive worldwide license to develop, manufacture, and commercialize Program Products directed to the Amylin Target. iBio must pay AstralBio a $750,000 upfront fee (due within 30 days) and future milestone payments (amounts redacted; structure ties to equity or cash depending on listing status), plus a percentage of Program Product Licensing Proceeds. AstralBio retains a non-exclusive, royalty-free license to use assigned IP for non-Amylin-Target products.
Why this rating
Asset acquisition with upfront payment of $750K (~3.3% of market cap) plus milestone obligations; exclusive right to commercialize Amylin Target. Material for small biotech but contingent on development success.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $1.42 ▲ 0.01% | at our read · backfill $1.42 | +10 min · backfill $1.42 ▲ 0.00% | +1 hr · backfill $1.38 ▼ 2.43% | +4 hrs · backfill $1.37 ▼ 3.84% |
The stock had already moved -0.01% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from August 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.